Under a tenth of people who could benefit from weight-loss injections including Wegovy can access them, states the WHO as it releases its initial recommendations on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to GLP-1 medication.
Per projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are key barriers to widespread availability to the treatments that can assist patients in reducing considerable body mass, says the body.
Skinny Jab Shortage
Despite the present most optimistic case, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of the global need, per the health organization.
The guideline urges countries and companies to expand access, through strategies including voluntary licensing.
Exclusive production rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so people eat less.
Individuals usually start to lose weight in the initial weeks of beginning the once-weekly jabs.
Studies indicates people may see weight return a year later of discontinuing the drug, as their normal appetite come back.
Being carrying excess weight elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight impacts people in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
